Cargando…
Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies
Immediately from the outset of the COVID-19 pandemic, researchers from diverse biomedical and biological disciplines have united to study the novel pandemic virus, SARS-CoV-2. The antibody response to SARS-CoV-2 has been a major focus of COVID-19 research due to its clinical relevance and importance...
Autores principales: | Yuan, Meng, Liu, Hejun, Wu, Nicholas C., Wilson, Ian A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7547570/ https://www.ncbi.nlm.nih.gov/pubmed/33069360 http://dx.doi.org/10.1016/j.bbrc.2020.10.012 |
Ejemplares similares
-
Protective neutralizing epitopes in SARS‐CoV‐2
por: Liu, Hejun, et al.
Publicado: (2022) -
An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain
por: Wu, Nicholas C., et al.
Publicado: (2020) -
Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2
por: Yu, Fei, et al.
Publicado: (2020) -
Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain
por: Wheatley, Adam K., et al.
Publicado: (2021) -
Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain
por: Chi, Xiaojing, et al.
Publicado: (2020)